Company intelligence / Profile preview

ShiraTronics

Minneapolis, Minnesota, United Statesshiratronics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The ShiraTronics Migraine Therapy System has shown promising results in pilot studies, including significant reductions in headache days per month (from an average of ~19 to ~7 after twelve weeks), decreased severity and duration of attacks, and improved quality-of-life scores. The system received FDA Breakthrough Device designation in 2021 and is currently being evaluated in the RELIEV-CM2 pivotal clinical study for safety and effectiveness.

Therapeutic areas: Neurology
Modalities: DeviceNeuromodulation therapy
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on ShiraTronics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ShiraTronics.

Explore the full profile